drugset / Trial / NCT03146637
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
Phase 2
Unknown
80 enrolled
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Beijing 302 Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for liver cancer.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2021-01-27
- Completion
- 2021-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Activated CIK | Cell therapy | — | — |
| Comparator | CIK | Cell therapy | — | — |